Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study

Survival is generally poor for Chinese patients with advanced melanoma because of high rates of acral and mucosal melanoma and limited therapeutic options. The first analysis of the phase 1b KEYNOTE-151 study showed second-line pembrolizumab was well tolerated and had clinically meaningful antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Lu, Zhang, Xiaoshi, Shu, Yongqian, Pan, Hongming, Wu, Di, Liu, Jiwei, Mao, Lili, Wang, Xuan, Wen, Xizhi, Gu, Yanhong, Zhu, Lingjun, Lan, Shijie, Cai, Xin, Diede, Scott J., Dai, Haiyan, Niu, Cuizhen, Li, Jianfeng, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593700/
https://www.ncbi.nlm.nih.gov/pubmed/36304457
http://dx.doi.org/10.3389/fimmu.2022.882471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593700/
https://www.ncbi.nlm.nih.gov/pubmed/36304457
http://dx.doi.org/10.3389/fimmu.2022.882471

Ejemplares similares